Comparison of F-18 FDG and C-11 Acetate PET in Multiple Myeloma


About this study

Investigators are doing this study to determine which of four imaging techniques: Fludeoxyglucose Positron Emission Tomography (18 FDG PET) computerized tomography (CT), 18 FDG PET Magnetic resonance imaging (MRI), C-11 acetate PET CT, and C-11 acetate PET MRI) is the best test for finding sites of active myeloma disease.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Patients being staged for multiple myeloma as follows: new diagnosis, high risk smoldering multiple myeloma, relapsed as defined by investigator
  • Patients who have undergone standard of care workup
  • 300 pounds or less
  • Can provide informed consent
  • Scheduled for a clinically indicated F-18 FDG PET scan
  • English speaking

Exclusion Criteria:

  • Pregnant, breast feeding
  • Concurrent active non-multiple myeloma malignancy
  • Contraindication to PET MRI
  • Previous Type I or Type II Diabetes mellitus or a fasting blood glucose >150 mg/dl

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Michael Roarke, M.D.

Closed for enrollment

More information


Publications are currently not available

Mayo Clinic Footer